Cardiovascular Systems Inc (CSII): Capital Management Llc Camber , 10% owner of Cardiovascular Systems Inc sold 1,100,000 shares on Sep 19, 2016. The Insider selling transaction was reported by the company on Sep 21, 2016 to the Securities and Exchange Commission. The shares were sold at $23.39 per share for a total value of $25591498 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 21, 2016, Capital Management Llc Camber (10% owner) sold 1,100,000 shares at $23.39 per share price.On Sep 9, 2016, Paul A. Koehn (SVP Manufacturing & Operations) sold 5,969 shares at $25.02 per share price.Also, On Aug 24, 2016, Laura Gillund (Chief Talent Officer) sold 1,395 shares at $23.93 per share price.On Aug 24, 2016, Kevin J. Kenny (Chief Operating Officer) sold 3,166 shares at $23.95 per share price.
Cardiovascular Systems Inc: On Tuesday, Sep 21, 2016 heightened volatility was witnessed in Cardiovascular Systems Inc which led to swings in the share price. The shares opened for trading at $23.43 and hit $23.99 on the upside , eventually ending the session at $23.85, with a gain of 1.97% or 0.46 points. The heightened volatility saw the trading volume jump to 14,09,817 shares. The 52-week high of the share price is $25.22 and the company has a market cap of $795 M . The 52-week low of the share price is at $7.5.
Company has been under the radar of several Street Analysts.Cardiovascular Systems Inc is Upgraded by Leerink Partners to Outperform. Earlier the firm had a rating of Mkt Perform on the company shares. The Rating was issued on Aug 22, 2016.Cardiovascular Systems Inc is Reiterated by Needham to Buy and the brokerage firm has raised the Price Target to $ 27 from a previous price target of $23 .The Rating was issued on Aug 4, 2016.Cardiovascular Systems Inc is Upgraded by BofA/Merrill to Neutral. Earlier the firm had a rating of Underperform on the company shares. The Rating was issued on Aug 4, 2016.Cardiovascular Systems Inc is Reiterated by Needham to Buy and the brokerage firm has raised the Price Target to $ 23 from a previous price target of $20 .The Rating was issued on Jun 29, 2016.
Cardiovascular Systems Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary arterial diseases. It has developed an orbital atherectomy technology for peripheral and coronary commercial applications. Its peripheral arterial disease systems are catheter-based platforms that treat plaque types in leg arteries both above and below the knee. Its products include Stealth 360 degree Peripheral Orbital Atherectomy System (OAS); the Diamondback 360 Peripheral OAS (Diamondback 360 Peripheral) and Diamondback 360 Peripheral Diamondback 360 60cm Peripheral OAS and Diamondback 360 4 French 1.25 Peripheral (collectively called as peripheral arterial disease systems (PAD systems)). Its coronary product the Diamondback 360 Coronary OAS (CAD System) is a catheter-based platform designed to facilitate stent delivery in patients with coronary arterial disease (CAD). The CAD System design is customized for the coronary application.